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Clinical practice guidelines are an increasingly impor-
tant driver of decisions about patient care. They have been
defined as ‘‘recommendations intended to optimize patient
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licenses/by-nc-nd/3.0/).and an assessment of the benefits and harms of alternative
care options’’ [1]. Guidelines have traditionally been devel-
oped to simply provide guidance for clinical decision mak-
ing, but they are becoming embedded in the structure of
UK primary care through their translation into indicators
of quality of care in a national ‘‘pay for performance’’
financial incentive scheme (the Quality and Outcomes
Framework) and through the development of quality stan-
dards to inform decisions on health care planning and
commissioning [2]. This increasing use of guidelines to
develop incentives and standards for primary care may lead
to more patients at lower risk of adverse outcomes
receiving treatment and exposure to potential adverse
effects.
Groups developing guidelines about the care of primary
care patients will use the current best evidence from pri-
mary care or lower risk populations where it exists. If
high-quality primary care evidence is not found, the best
evidence available may be from a secondary care or higheress article under the CC BY-NC-ND license (http://creativecommons.org/
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 The applicability of clinical practice guidelines to
primary care has been questioned for individual
conditions such as hypertension and depression,
and concerns have been raised about guidelines
promoting overtreatment of low-risk populations.
 Until now, evidence from a systematic appraisal of
the relevance to primary care of published guide-
lines has been lacking.
 Nearly two-third of the research cited in support of
National Institute for Health and Care Excellence
guideline recommendations for primary care was
of uncertain relevance to primary care patients,
with little or no acknowledgment of this
uncertainty.
 Guideline development groups should more clearly
identify which recommendations are intended for
primary care and uncertainties about the relevance
of the supporting evidence to primary care patients,
to avoid potential overtreatment and adverse
effects.
risk population. This entirely appropriate approach leads to
problems when a guideline development group (GDG) as-
sumes that the evidence from research conducted on a high-
er risk population can automatically be applied to a lower
risk primary care population. If uncertainty about the evi-
dence is not explicitly acknowledged, the integrity of the
guideline is compromised and patient harm may result
[3,4]. The benefits of treatment are usually lower in popu-
lations at lower risk of adverse outcomes, whereas the risk
of harm from adverse treatment effects remains constant.
Patients seen in primary care typically have less severe
illness than those in hospital, and so evidence from trials
conducted in secondary care may have limited relevance
and result in harms outweighing benefits [5].
An example of taking evidence from a higher risk popula-
tion and applying it to a lower risk population is the Quality
and Outcomes Framework indicator and National Institute
for Health and Care Excellence (NICE) heart failure guide-
line recommendation that all primary care patients with
chronic heart failure (including low grade) should be offered
b-blockers and ACE inhibitors. This indicator is supported
by evidence generalized from higher risk populations (New
York Heart Association grades IIIeIV), in which there is
clear evidence of benefit, to lower risk populations, in which
the evidence of benefit is more equivocal. The potential harm
is the adverse effects of b-blockers experienced by some pa-
tients, and the substantial risk of acute kidney injury from
ACE inhibitors, whichmay account for a tenth of the increase
in hospital admissions because of an acute kidney injury [6].
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fits might be in a typical primary care patient [7,8], and a gen-
eral practitioner needs to know about this uncertainty when,
for example, considering prescribing a b-blocker to a patient
with a relative contraindication to a b-blocker therapy from a
comorbid condition. This vital information about uncertainty
and the balance of benefits and harms is hard to find in the
Quality and Outcomes Framework guidance or NICE guide-
line, which presents a single approach rather than acknowl-
edging that there are several acceptable alternatives for
low-risk patients.
Another example where it is hard for the user of a clinical
guideline to know about the balance of benefits and harms for
a typical primary care patient is the Quality and Outcomes
Framework incentive to prescribe aspirin or an alternative an-
tiplatelet to all patients with peripheral arterial disease, most
of whom do not have symptoms and are managed in primary
care [9]. The evidence that antiplatelet therapy can reduce
serious vascular events comes primarily from a large sub-
group analysis of the Antithrombotic Trialists’ Collaboration
meta-analysis in high-risk patients and a similar review con-
ducted by NICE [10,11]. However, the authors caution that
their results may not be applicable to low-risk patients, and
others have calculated that the number of potential reductions
in coronary heart disease events exceeded the number of po-
tential precipitated adverse bleeding events only for patients
with a 1% or greater annual risk of coronary heart disease
events [12]. A third example is chronic kidney disease
(CKD), where there is evidence of benefit to high-risk popu-
lations but no evidence of benefit in people with early-stage
CKD at a low risk of future disease [13]. Both primary care
physicians and specialists have expressed concerns about po-
tential harms from overtreatment resulting from expanding
definitions of CKD in guidelines.
A small pilot study suggested that the evidence base for pri-
mary care guidelines might not be relevant to most primary
care patients, with important implications for patient safety
[14], and we wanted to systematically examine the evidence
base for clinical guidelines used in primary care. We used
guidelines from the NICE as it has been a leading provider
of evidence-based clinical guidelines in the United Kingdom
since 2002 [15]. NICE’s highly respected methods compare
well with the U.S. Institute of Medicine’s standards for trust-
worthy guidelines [1,16e18] and with the international
consensus that guidelines should be developed using an
explicit and transparent process that minimizes distortions,
biases, and conflicts of interest; should base recommendations
on a systematic review of the existing evidence; should
include experts and patient representatives on a multidisci-
plinary GDG; and should consider important patient sub-
groups and patient preferences [1,19,20]. The development
ofNICE clinical guidelines follows awell-established process
[16]. When a topic has been chosen, a National Collaborating
Centre (NCC) is commissioned to develop the guideline. The
NCCprepares the scopewhich sets outwhat the guidelinewill
andwill not cover and recruits theGDG.Review questions are
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the technical team, which the GDG uses to formulate recom-
mendations. We aimed to measure the percentage of primary
care relevant publications in the cited evidence base for NICE
primary care recommendations, for all NICE guideline rec-
ommendations for primary care published over 2 years.
2. Methods
We reviewed the scope of all 45 clinical guidelines pub-
lished by NICE in 2010 and 2011 and excluded any guide-
line explicitly aimed at noneprimary care settings. Five
academic family physicians on the research team classified
recommendations in the remaining guidelines as specific,
relevant, or not relevant to primary care, using our previously
piloted methods [14]. Two reviewers independently rated
each recommendation and then discussed any discrepancies
by telephone and/or e-mail. If they could not reach
consensus on a recommendation, it was sent to a third
reviewer and then classified according to the majority view.
Reviewers used the following definitions, along with exam-
ples: ‘‘primary care specific recommendations inform deci-
sions that are almost always made by primary care
providers such as general practitioners’’ and ‘‘primary care
relevant recommendations inform decisions that could be
made by health professionals in either primary care or
another setting.’’ We included guidelines if more than 50%
of the recommendations were judged relevant to primary
care or if at least one recommendation was specific to pri-
mary care. We included all primary careespecific or -rele-
vant recommendations within these selected guidelines.Fig. 1. Flow chart for selection of guidelines, recWe reviewed all publications cited as evidence for
included recommendations and classified each publication
according to whether the study population had been
selected from primary care or community settings (ie, not
from hospital outpatient or inpatient populations). We clas-
sified publications as ‘‘unclear’’ if we could not obtain this
information from these or related publications. We consid-
ered systematic reviews as a single publication and
included them if at least one study in the review had been
conducted on a primary care or community population.
Publications were excluded from the study and not consid-
ered further if they referred to other guidelines, nonsystem-
atic reviews, or references that only appeared in the
guideline appendices with no apparent link to the recom-
mendations. The primary outcome was the percentage of
included cited publications that were relevant to primary
care. Secondary outcomes were guideline development
center, primary care membership of GDG, recommenda-
tions for further primary care research, whether ‘‘Grading
of Recommendations Assessment, Development and Eval-
uation’’ (GRADE) was used to assess the quality of
evidence [21], and the clarity of links from the recommen-
dation back to the supporting evidence base.3. Results
Twenty-two of the 45 guidelines were assessed as
relevant to primary care (Fig. 1). These 22 guidelines con-
tained 1,185 recommendations, and the reviewers consid-
ered 777 of them to be relevant to primary care. The twoommendations, and research publications.
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mendations in the same category of specific, relevant, or
not relevant to primary care, with discrepancies predomi-
nantly between the categories of primary care ‘‘specific’’
or ‘‘relevant.’’ After discussion between the two reviewers,
full agreement was reached on 1,166 (98.4%) of recom-
mendations. The remaining recommendations were classi-
fied after independent rating by a third reviewer.
Of the 777 recommendations, 282 were excluded as they
were based on GDG consensus in the absence of evidence or
were standard clinical practice (such as a recommendation to
take a history from the patient), leaving 495 (42%, range by
guideline 9e100%) recommendations that were both evi-
dence based and relevant to primary care (Table 1). The ev-
idence for these 495 recommendations came from 1,573
research publications. The links in the guideline from recom-
mendation back to supporting research sometimes appeared
to have become blurred in the process of developing the
guideline. The research was considered relevant to primary
care in 590 (38%, range by guideline 6e74%) of theseTable 1. Relevance to primary care of recommendations, and of publications
Institute for Health and Care Excellence (NICE)
Clinical guideline and development center
R
Total in guideline,
National Clinical Guideline Centre
CG95 Chest pain of recent onset 89
CG97 Lower urinary tract symptoms 82
CG100 Alcohol-use disorders 37
CG101 Chronic obstructive pulmonary diseasea 12
CG103 Delirium 27
CG108 Chronic heart failurea 25
CG109 Transient loss of consciousness 41
CG111 Nocturnal enuresis 99
CG126 Stable angina 50
CG127 Hypertensiona 37
Subtotal 499
National Collaborating Centre for Mental Health
CG113 Generalised anxiety disordera 49
CG120 Psychosis with coexisting substance misuse 78
CG123 Common mental health disorders 69
CG133 Self-harm (longer term management) 57
Subtotal 253
National Collaborating Centre for Women’s and Children’s Health
CG99 Constipation in children and young people 46
CG102 Bacterial meningitis 111
CG110 Pregnancy and complex social factors 53
CG128 Autism in children and young people 69
Subtotal 279
National Collaborating Center for Cancer
CG121 Lung cancera 91
CG122 Ovarian cancer 27
Subtotal 118
NICE Internal Short Clinical Guideline Technical Team
CG96 Neuropathic pain 17
CG116 Food allergy in children and young people 19
Subtotal 36
Total 1,185
Abbreviation: PCR, primary care relevant.
a Update of existing guidelines with only new recommendations includepublications (Table 1). The research was not considered
relevant to primary care in 916 publications. The relevance
to primary care was unclear in 67 publications, in which
the research population was not clearly described in the
original articles.
There was a wide variation across guidelines in the per-
centage of both recommendations and supporting publica-
tions that were relevant to primary care. In some guidelines
(eg, ‘‘pregnancy and complex social factors’’) both the rec-
ommendations (100%) and the evidence base (74%) were
judged to be relevant to primary care. Other guidelines (eg,
‘‘chronic heart failure’’ and ‘‘constipation in children and
young people’’) were relevant to primary care (68% and
72%, respectively) and yet were based on relatively little ev-
idence from primary care (10% and 17%). Guidelines in
mental health and women’s and children’s health had the
highest percentages of supporting publications that were
relevant to primary care (51% and 52%).
The number of primary care providers on GDGs ranged
from 0 to 4 (12% of all GDG membership; Table 2). Familycited as evidence, for all included clinical guidelines from the National
ecommendations Publications
N PCR, N
PCR and evidence
based, N (%) Cited as evidence, N PCR, N (%)
48 48 (54) 48 20 (42)
48 22 (27) 92 13 (14)
15 5 (14) 22 2 (9)
12 10 (83) 24 9 (38)
27 24 (89) 129 8 (6)
22 17 (68) 48 5 (10)
28 17 (41) 35 21 (60)
93 39 (39) 103 35 (34)
32 19 (38) 35 9 (26)
37 24 (65) 147 66 (45)
362 225 (45) 683 188 (28)
46 35 (71) 124 58 (47)
45 20 (26) 27 14 (52)
68 23 (33) 63 45 (71)
51 24 (42) 147 66 (45)
210 102 (40) 361 183 (51)
37 33 (72) 75 13 (17)
22 18 (16) 35 11 (31)
53 53 (100) 137 101 (74)
35 6 (9) 91 52 (57)
147 110 (75) 338 177 (52)
11 11 (12) 12 1 (8)
11 11 (41) 30 12 (40)
22 22 (100) 42 13 (31)
17 17 (100) 95 12 (13)
19 19 (100) 54 17 (31)
36 36 (100) 149 29 (19)
777 495 (42) 1,573 590 (38)
d.
Table 2. Guideline development group (GDG) membership and primary care research recommendations
Clinical guideline and development center
Primary care providers
on GDG, N (% of GDG)a
Family
physician
Academic family
physician
Practice (office)
nurse
Further primary
care research
recommended
National Clinical Guideline Centre
CG95 Chest pain of recent onset 1 (7) 1 0 0 No
CG97 Lower urinary tract symptoms 2 (17) 2 0 0 No
CG100 Alcohol-use disorders 1 (7) 1 0 0 No
CG101 Chronic obstructive pulmonary disease 3 (25) 2 0 1 Yes
CG103 Delirium 0 (0) 0 0 0 Yesb
CG108 Chronic heart failure 3 (30) 2 1c 0 Yesd
CG109 Transient loss of consciousness 2 (13) 2 0 0 No
CG111 Nocturnal enuresis 1 (8) 1 0 0 No
CG126 Stable angina 2 (15) 2 0 0 No
CG127 Hypertension 4 (40) 2 1 1 No
Subtotal 19 (15) 15 2 2 3/10
National Collaborating Centre for Mental Health
CG113 Generalised anxiety disorder 2 (18) 0 2 0 Yes
CG120 Psychosis with coexisting substance misuse 0 (0) 0 0 0 No
CG123 Common mental health disorders 4 (29) 1 2c 1 Noe
CG133 Self-harm (longer term management) 1 (7) 1 0 0 No
Subtotal 7 (13) 2 4 1 1/4
National Collaborating Centre for Women’s and Children’s Health
CG99 Constipation in children and young people 1 (8) 1 0 0 No
CG102 Bacterial meningitis 1 (7) 0 1 0 Yes
CG110 Pregnancy and complex social factors 1 (7) 1 0 0 No
CG128 Autism in children and young people 1 (8) 1 0 0 No
Subtotal 4 (7) 3 1 0 1/4
National Collaborating Centre for Cancer
CG121 Lung cancer 1 (5) 0 1 0 No
CG122 Ovarian cancer 1 (7) 0 1 0 No
Subtotal 2 (6) 0 2 0 0/2
NICE Internal Short Clinical Guidelines Technical Team
CG96 Neuropathic pain 1 (9) 0 1 0 No
CG116 Food allergy in children and young people 1 (9) 1 0 0 Yes
Subtotal 2 (9) 1 1 0 1/2
Total (22 guidelines) 34 (12) 21 10 3 6/22
a GDG membership excludes technical team.
b Recommended research in a long-term care setting but did not explicitly identify primary care.
c Academic family physician chaired the guideline development group.
d Recommended research in the general population.
e Mentioned primary care in the justification to one research recommendation.
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The percentage of primary care providers on GDGs was
not associated with the percentage of primary care relevant
studies (correlation coefficient, 0.15). Further research in
primary care was called for in 6 of the 22 full guidelines.
Nine of the 22 included guidelines used elements of
GRADE to assess the quality of included evidence
[21e23]. These guidelines were published after NICE
introduced GRADE in 2009 [23].4. Discussion
Nearly two-third of the research cited in support of
NICE guideline recommendations for primary care was of
uncertain relevance to primary care patients, with little or
no acknowledgment of this uncertainty in the published
guideline. Only 38% of cited publications were based on
patients typical of primary care. In many guidelines, the
link from evidence to recommendation was not explicit.Where evidence was available, many studies did not report
the setting or population used for the research.
The low percentage (38%) of studies relevant to primary
care is likely to be due to the lack of suitable primary care
research. This correctly requires GDGs to extrapolate from
research that has been conducted on other, often higher
risk, populations. The difficulty for the guideline user is
not so much that the evidence is inevitably incomplete,
but rather that it is not clear which recommendations are
supported by primary careebased relevant evidence and
which by evidence from other clinical settings or by
consensus of the GDG. Judgments about the relevance of
the evidence to different populations made using GRADE’s
‘‘indirectness’’ domain [21] were useful but presented as a
minor part of GRADE which did not come through clearly
in final guidelines. Family physicians are experienced in
managing clinical uncertainty and making decisions with
incomplete information [24], and when deciding about
treatment for a patient, they need to know the extent to
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[25,26]. Information about uncertainty in the research, and
potential applicability to a patient in primary care, is not
currently easily accessible in guidelines in the way it needs
to be to improve clinical decision making in primary care
and avoid accusations of guideline bias [3,27].
Other authors have noted the difficulties in applying
guidelines where there are important differences between
trial participants and typical primary care patients in hyper-
tension [5,28]. Only one group has looked specifically at
whether guidelines are supported by evidence from primary
care: a group in the Netherlands looked at 13 guidelines for
depression and screened 804 publications, to find only two
studies based in primary care [29]. They concluded that the
guideline recommendations could not be considered evi-
dence based. Our research is the first systematic appraisal
of national guidelines, and our results show that uncertain
applicability of cited research to patients in primary care
is a problem shared to a greater or lesser degree by all
the guidelines reviewed.
Strengths of the research include that it was based on a
large sample of all recent NICE guidelines and used piloted
methods [14]. The estimate of 38% of evidence being based
on patients typical of primary care is likely to be an overesti-
mate rather than an underestimate, as we only included
guidelines with most recommendations relevant to primary
care (in which the proportion of primary care evidence is
likely to be greater than in other guidelines). The biggest
challenge for the research teamwas to classify the guidelines,
recommendations, and research studies in turn as either rele-
vant to primary care or not. We used transparent and piloted
methods, but the choice between ‘‘relevant’’ and ‘‘not rele-
vant’’ was not always straightforward, and other groups
might make different decisions in the gray areas. We re-
sponded to this uncertainty using a generous definition for
classifying study populations as relevant to primary care,
which again would tend to make the 38% an overestimate
rather than an underestimate.
Future research is needed into the dynamics and ap-
proaches to reaching informal consensus used by GDGs
and the influence of variable factors such as professional
background and conflicts of interest [3]. Internationally, pri-
mary and community care is usually of lower technology than
hospital care, and so contextualizing research within the
primary care setting is relevant to both developed and devel-
oping countries. The extent to which research in high-
technology settings can be considered relevant for guideline
users in low-technology settings in low- and middle-income
countries is under-researched.
Frameworks such as the Appraisal of Guidelines for
Research & Evaluation Instrument (AGREE II) to assess
the quality of practice guidelines [20] and the GRADE tool,
which includes an ‘‘indirectness’’ domain to assess the
applicability to different populations [22,23], have been
developed to improve the integrity of clinical guidelines.
NICE and other national guideline developers contributeto and follow this good practice, have primary care mem-
bership of GDGs, try to ensure that secondary care content
experts do not dominate discussions regarding recommen-
dations for primary care, and involve the public in the pro-
cess [30,31], and these frameworks and methods should
continue to be developed and applied. However, despite
all the good practice, it is still hard for a primary care clini-
cian to find the information they need to guide a decision
about the potential benefits and harms of treatment. Guide-
line developers intend to present their recommendations
with enough information for the user to track back to the
strength of the underlying evidence, should they need to
do so [1,16,19], but we found that ‘‘tracking back’’ to the
evidence was usually very difficult. The relevance of pub-
lished clinical practice guidelines to primary care patients
is still too opaque.5. Conclusion
An enhanced approach is needed to avoid the assump-
tion of generalizability of research evidence from high-
risk research populations to low-risk primary care patients
and reduce potential overtreatment and avoidable harm.
More explicit consideration of the primary care context is
needed at all stages of development, to reduce dependence
on the influencing skills of a primary care provider on the
GDG. The relevance to primary care should be carefully
considered at initial scoping. For relevant guidelines, the
initial review questions for the evidence search should then
be considered specifically for relevance to primary care,
perhaps as a subgroup in the search, and negative findings
reported if evidence is not found. Primary care relevance
could be considered in terms of setting, severity of illness,
or risk group depending on the guideline’s intended audi-
ence. The guideline should be specific about where primary
care research has or has not been used, including limita-
tions or lack of evidence, and research recommendations
where relevant primary care evidence is lacking should be
clearly badged. Uncertainties in the evidence should always
be clearly presented and not lost in the understandable
desire to produce straightforward recommendations. A shift
in focus during guideline development to outcomes (such as
health gain) as opposed to simple processes (such as phar-
maceutical prescription) has been proposed and should be
encouraged [2].
An enhanced primary care perspective could come from
either greater involvement from the outset of primary care
professionals with relevant content expertise where feasible
or from more explicit guidance to development groups
combined with systematic checks at all stages of guideline
development. Checks for compliance with development
manuals and frameworks such as GRADE and AGREE II
would help ensure, for example, that GRADE profiles prop-
erly address issues of indirectness [16,20,22]. At least one
NICE committee has already started to consider research
data that have been reanalyzed to show the results
1257N. Steel et al. / Journal of Clinical Epidemiology 67 (2014) 1251e1257separately for low- and high-risk populations [32], with a
consequent change in the decision made. Success will be
when a clinical guideline user can quickly and accurately
determine the broad relevance of each recommendation to
their patient, including uncertainties, and can easily track
back from the recommendation to the underlying evidence
base, should they wish to do so.Acknowledgments
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